DHA-PQP dispersible

Alfasigma

Product category
  • Artemisinin-based Combination Therapy (ACT)

  • Dihydroartemisinin-piperaquine

Therapeutic indication
  • Treatment of uncomplicated P. falciparum malaria in children and infants >5kg
Dosing
  • Once-daily for 3 days

Efficacy
  • Still under investigation

  • 28-day PCR-corrected ACPR* 94.7–99.9% (TBC)

  • 42-day PCR-corrected ACPR* 91.5–99.3% (TBC)

Key features
  • Anticipated comparatively long post-treatment protection

Challenges
  • Cardiac monitoring restrictions 

  • Confirmed piperaquine resistance in Greater Mekong Sub-region (GMS)

Status
  • Pharmacokinetic studies in children completed 

  • Dossier under development for submission to EMA

Next milestone
  • Submission to EMA planned for end 2018 / beginning 2019 

* ACPR = adequate clinical and parasitological response